Poly Pharm Receives U.S. Marketing Approval for New Specification of Benzenesulfonium Atracurium Injection

 
Recently, FDA marketing authorization was granted for additional sizes of benzenesulfonium atracurium injection: 10mg/5ml and 200mg/20ml. Previously, Puli Pharma‘s benzenesulfonium atracurium injection (20mg/10ml) has been granted marketing authorization in March 2024 by the FDA.

  This marks that the benzenesulfonium atracurium injection (multi-specification) produced by Puli Pharma is simultaneously qualified to be marketed and sold in the U.S., which can meet the different requirements of individualized dosage, and will have a positive impact on the company‘s expansion into the U.S. market.

   Benzenesulfonium atracurium is a commonly used muscle relaxant, which is mainly used in general anesthesia, surgical operation and intensive care treatment to help patients‘ muscle relaxation and facilitate surgical operation and mechanical ventilation.

   Benzenesulfonium atracurium is a non-depolarizing neuromuscular blocking agent and is classified as a muscle relaxant in the category of high-risk drugs, class C high-risk drugs. It blocks neuromuscular transmission primarily by antagonizing the action of acetylcholine through competitive binding to cholinergic receptors on the motor endplate.